Navigation Links
Research explores how breast cancer spreads and new ways to treat it
Date:8/3/2011

ORLANDO, Fla. August 3, 2011 Research into new methods to prevent and slow metastatic breast cancer will be presented this week at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program (BCRP). Approximately 6 percent of women with breast cancer will have metastatic disease upon diagnosis, and up to 30 percent of node-negative and 70 percent of node-positive breast cancers will relapse. 1 Common sites for breast cancer to spread are to the lungs, liver, brain and bones.

Studies presented at Era of Hope evaluate early research on a vaccine for HER2+ breast cancer that has stopped responding to treatment is entering human clinical trials later this year will also be discussed.

"New treatments for metastatic breast cancer are needed, as many patients become resistant to existing therapies," said Captain Melissa Kaime, M.D., Director of the Congressionally Directed Medical Research Programs (CDMRP), under which the BCRP is managed. "The novel studies presented at Era of Hope explore a number of promising pathways for treatment and new targets for preventing the spread of cancer."

Dissecting Tumor Stromal Interactions in Breast Cancer Bone Metastasis
Principal Investigator: Yibin Kang, PhD, Princeton University

Between 60 and 80 percent of late-stage breast cancer patients eventually face bone metastasis. 2 Discovering bone metastasis genes that are clinically relevant and functionally important are critical for the development of novel therapeutics for breast cancer patients.

In this study, a multidisciplinary approach was applied to analyze the molecular basis of breast cancer bone metastasis, combining tools to analyze genomic information with animal models and clinical analysis of cancer metastasis. Candidate genes, including one dependent on EGFR 3 (Epidermal Growth Factor Receptor), and a TGFb (Transforming Growth Factor-beta) target gene called Jagged1 were identified. The study revealed a network of molecular crosstalk between tumor and bone cells using Jagged1 in tumor cells, EGFR in bone cells and TGFb released from damaged bone. Such pathological tumor-host tissue interactions eventually lead to tumor expansion and bone destructions. Targeting these pathways can reduce the development of bone metastasis and provide new avenues for managing the progression of the disease to the bones.

"We are excited to have identified new genetic markers for patients at high risk for bone metastasis, which may provide additional potential targets for preventing and treating the disease," said Dr. Yibin Kang of Princeton University.

Rapid Translation of a Novel and Potent Vaccine in HER2+ Metastatic Breast Cancer Patients
Principal Investigator: Kim Lyerly, MD, Duke Medical Center

Approximately 20 percent of breast cancers are HER2+, meaning they over-express the HER2 gene, resulting in a particularly aggressive form of the disease.4 The first targeted treatment approved to treat HER2+ breast cancer was Herceptin (trastuzumab) in which the BCRP provided the early funding for research leading to the development of monoclonal antibodies against the HER2 receptor. However, despite its specificity, many patients experience resistance.5 Researchers at Duke University Medical Center evaluated a novel viral vector vaccine combination for testing in trastuzumab-refractory breast cancer patients.

Viruses attack and invade host cells by injecting their DNA as part of their replication process. In vaccine development, viruses can be used in this way to bring disease-fighting genetic information inside human cells.6 In this study, the two viral vectors, an adenovirus construct (Ad-HER2) and an alphavirus VRP construct (VRP-HER2), when used together in animal models have shown to elicit potent immune responses capable of halting the growth of and directly killing human breast cancer cells that are resistant to trastuzumab. Duke researchers, in seeking to prepare and submit an Investigational New Drug (IND) application for the U.S. Food and Drug Administration (FDA), have demonstrated through preclinical research that the vaccine is potent, does not cause tumor development, and is compatible with lapatinib, another treatment specifically targeting HER2+ breast cancer. Both viral vectors are currently undergoing preclinical toxicology studies and are expected to enter the clinic in the third quarter of 2011.

"Patients with HER2+ breast cancer often face the reality of relapse," said Dr. Kim Lyerly of Duke University Medical Center. "We are excited about continuing this translational-based, cutting-edge vaccine strategy, and potentially bringing them a new way to fight the disease."


'/>"/>

Contact: Dayna Hochstein
dhochstein@spectrumscience.com
202-955-6222
US Department of Defense Congressionally Directed Medical Research Programs
Source:Eurekalert

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. 2010 HSR Impact Award recognizes surgical safety research
3. MSU launches first anti-counterfeiting research program
4. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
5. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
6. Researchers discover new way to kill pediatric brain tumors
7. Family Research Council: Planned Parenthood Report Oversexualizes Ten-Year-Olds, Undermines Parental Authority
8. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
9. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
10. International Diabetes Federation awards $2 million to 9 global diabetes research projects
11. Gladstones Robert Mahley to receive Research!America advocacy award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... and domain expertise for sponsors and CROs to speed clinical development, has ... (RTSM) software platform. Bioclinica AGILE RTSM provides seamless clinical supply ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a ... first in a new class of photodynamic cosmetics (PDC). , Allumera® is the ... reduce outward signs of aging, and minimize the appearance of pores – all ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab ... to be the preferred physical therapy provider for Derby City CrossFit, effective immediately. ... City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will ...
(Date:4/25/2017)... ... ... A stressful work environment can hurt the physical and emotional health of employees. ... workplace. The goal of Clearview Resolution Services has always been to help others, starting ... will be shutting down the office early on Fridays. The Clearview team will use ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... attempts to compare student test score performance for the 2015-16 school year across ... state’s voucher programs. Though it highlights important patterns in student test score performance, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
Breaking Medicine Technology: